A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week

Inclusion Criteria:

1. Subjects aged 22 years and older

2. Subjects with Chronic Idiopathic Constipation (CIC) according to Rome III criteriaand who have not experienced relief of their symptoms from available therapies

3. Subjects with an average of <3 Spontaneous Bowel Movements (SBM) per week and ≥1 SBMper week

4. Normal colonoscopy performed within 10 years prior to study participation, unlessthe subjects are <50 years old and without alarm signs and/or symptoms

5. Subject signed the Informed Consent Form (ICF)

6. Female subjects must have a negative pregnancy test

Exclusion Criteria:

1. History of complicated/obstructive diverticular disease

2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.

3. History of significant gastrointestinal disorder, including any form of inflammatorybowel disease or gastrointestinal malignancy (celiac disease is accepted if thesubject has been treated and is in remission)

4. History of gastroparesis

5. Use of any of the following medications:

• Medications that may affect intestinal motility, prokinetics, anti-depressants,anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers,aluminum/magnesium hydroxide

• With the exception of antidepressants, thyroid or hormonal replacement therapy,when the subject has been on a stable dose for at least 3 months prior toenrollment.

6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic,biliary, endocrine, psychiatric or neurologic disease.

7. Presence of cardiac pacemaker or gastric electrical stimulator.

8. History of, or current eating disorders, such as anorexia, bulimia, or compulsoryovereating.

9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinicallysignificant rectocele, history of intestinal resection (with an exception forappendectomy, cholecystectomy and inguinal hernia repair), history of bariatricsurgery or evidence of any structural abnormality of the gastrointestinal tract thatmight affect transit

10. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophagealstricture or achalasia

11. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)

12. Subjects with pelvic floor dysfunction/defecatory disorder

13. Participation in another clinical study within one month prior to screening.

14. Women who are pregnant or lactating